Desmoid tumors are rare, non-cancerous growths that arise from fibroblasts, the cells responsible for building connective tissue and healing wounds. Despite being classified as benign, they behave aggressively at their site of origin, invading nearby tissue and often causing significant pain. They affect roughly 3 to 5 people per million each year, most commonly appearing between ages 20 and 44, and are two to four times more common in women than men.
What makes desmoid tumors unusual is this contradiction: they never spread to distant organs the way cancer does, yet they can cause serious problems by growing into surrounding structures. That behavior puts them in a category of their own and makes treatment decisions uniquely complex.
Where Desmoid Tumors Grow
Desmoid tumors can develop almost anywhere connective tissue exists, but they fall into three broad categories based on location: extra-abdominal (shoulders, chest wall, legs, arms), abdominal wall, and intra-abdominal (inside the abdomen, often around the intestines). About 84% of cases are sporadic, meaning they occur without a known inherited condition, and these can appear at virtually any site. The remaining cases are linked to an inherited condition called familial adenomatous polyposis (FAP), and those tumors tend to develop in the abdominal wall or inside the abdomen.
Location largely determines how the tumor affects your body. Extra-abdominal tumors typically present as a slow-growing, firm lump that you or your doctor can feel. Intra-abdominal tumors are trickier because they often grow silently until they’re large enough to press on surrounding organs. That compression can block the intestines, squeeze blood vessels and cut off circulation to sections of bowel, or press on the tubes connecting the kidneys to the bladder. In rare cases, intra-abdominal desmoids cause emergencies like bowel perforation or abscess formation that require urgent surgery.
Causes and Genetic Drivers
Most sporadic desmoid tumors are driven by a mutation in a gene called CTNNB1, which controls a signaling protein involved in cell growth. In a study of 254 sporadic desmoid tumors, 88% carried this mutation. When the gene malfunctions, fibroblast cells receive constant “grow” signals, producing excess collagen-rich tissue that forms the tumor mass.
A smaller group of desmoid tumors is linked to FAP, a hereditary condition caused by mutations in a different gene (APC). People with FAP have a lifetime risk of developing a desmoid tumor as high as 21%. If you’ve been diagnosed with FAP, your medical team will typically monitor you for desmoid development, particularly after abdominal surgery, which can trigger their growth. Pregnancy, trauma, and hormonal changes have also been associated with desmoid tumor development, though many cases arise without any identifiable trigger.
Symptoms and How They Feel
Most desmoid tumors present as slow-growing, painless masses. You might notice a firm lump under your skin that gradually gets bigger over weeks or months. Pain develops in many cases, sometimes from the tumor pressing on nerves or stretching surrounding tissue. The pain can range from a dull ache to something severe enough to interfere with daily activities and sleep.
Beyond pain and a visible or palpable lump, symptoms depend entirely on where the tumor sits. A desmoid in the shoulder or arm might restrict your range of motion. One growing near the intestines might cause cramping, nausea, or changes in bowel habits before progressing to a full obstruction. Some people experience no symptoms at all and discover the tumor incidentally during imaging for something else.
How Desmoid Tumors Are Diagnosed
MRI is the primary imaging tool for evaluating desmoid tumors. On MRI, these tumors display a characteristic range of signal patterns that reflect their internal composition. Areas with high signal intensity on a specific type of MRI sequence (called T2-weighted imaging) indicate higher water and cellular content, while low-signal areas suggest dense, fibrous tissue. This distinction matters because it helps predict behavior: tumors where 90% or more of the volume shows high T2 signal have a one-year progression-free survival of only 55%, compared to 94% for tumors with less extensive bright signal. In other words, the brighter and more uniformly a tumor lights up on MRI, the more likely it is to grow.
A biopsy, where a small tissue sample is removed and examined under a microscope, confirms the diagnosis. Testing for CTNNB1 mutations in the tissue sample helps distinguish desmoid tumors from other soft tissue growths that can look similar. Genetic testing for APC mutations may also be recommended, especially if you’re young or if the tumor is in the abdomen.
Treatment: Why Watching Often Comes First
The approach to desmoid tumors has shifted dramatically in recent years. Where surgery was once the default, expert guidelines now recommend active surveillance as the first step for most patients. This means regular imaging and symptom monitoring without immediate intervention. The reasoning is practical: desmoid tumors are unpredictable. Some grow steadily, some stabilize on their own, and a meaningful number actually shrink without any treatment. Jumping to surgery or medication before understanding how a particular tumor behaves can mean unnecessary side effects or complications.
Active management becomes necessary when symptoms get worse or the tumor keeps growing on successive imaging scans. Symptomatic progression alone, even without measurable growth on imaging, can justify starting treatment.
When Treatment Is Needed
For tumors that do progress, the first FDA-approved systemic therapy for desmoid tumors arrived in 2023. In the pivotal trial of 142 patients with progressing desmoid tumors that weren’t suitable for surgery, the treatment arm had such strong results that the median time before the disease worsened was never reached during the study period, while patients receiving a placebo progressed at a median of about 15 months. The drug works by blocking a cell signaling pathway that drives tumor growth, and an exploratory analysis showed it reduced the risk of radiographic progression by roughly 69%.
MRI also plays a role in tracking treatment response. Successful systemic therapy is associated with a decrease in T2 signal intensity on MRI, essentially the tumor becoming darker and more fibrous, which correlates with less active disease.
Surgery remains an option in select situations, particularly for abdominal wall tumors where the operation is relatively straightforward and the risk of complications is low. However, recurrence after surgery is a real concern. Studies show that when surgeons achieve clean margins (no tumor cells at the edges of the removed tissue), the recurrence rate is about 24%. When margins are positive, meaning some tumor cells were left behind, recurrence climbs to roughly 64%. This high recurrence rate is one of the key reasons the field moved toward watching and waiting rather than operating early. Radiation therapy is sometimes considered when surgery isn’t feasible, though it’s generally not a first-line approach.
Living With a Desmoid Tumor
Because desmoid tumors don’t metastasize, they aren’t life-threatening in the way traditional cancers are. But “benign” can be misleading. The pain, functional limitations, and anxiety of living with a tumor that might grow into critical structures take a real toll. For intra-abdominal tumors especially, the potential for serious complications like bowel obstruction means ongoing vigilance matters even during periods of stability.
Follow-up typically involves periodic MRI scans to track size and signal characteristics over time. The intervals between scans vary depending on whether the tumor is stable, growing, or responding to treatment. Many people with stable, asymptomatic desmoid tumors live with them for years without needing any intervention, while others cycle through multiple treatment approaches to manage a tumor that keeps progressing. The unpredictability is, in many ways, the defining challenge of the disease.